Cascades Reports Results for the Second Quarter of 2021, increases dividend 50%

Financial News
Tools
Typography
  • Good packaging market dynamics partially mitigate softness in the Tissue industry and inflationary pressure on production costs;
  • Dividend increased 50% reflecting commitment to shareholder value and confidence in long-term performance

KINGSEY FALLS, QC, Aug. 5, 2021 - Cascades Inc. (TSX: CAS) reports its unaudited financial results for the three-month period ended June 30, 2021.

Q2 2021 Highlights (comparative figures have been restated to reflect discontinued operation2

  • Sales of $956 million (compared with $942 million in Q1 2021 (+1%) and $1,020 million in Q2 2020 (-6%))
  • As reported (including specific items)
    • Operating income of $23 million (compared with $44 million in Q1 2021 (-48%) and $64 million in Q2 2020 (-64%))
    • Operating income before depreciation and amortization (OIBD)1 of $87 million (compared with $109 million in Q1 2021 (-20%) and $127 million in Q2 2020 (-31%))
    • Net earnings per share of $0.02 (compared with $0.22 in Q1 2021 and $0.57 in Q2 2020)
  • Adjusted (excluding specific items1)
    • Operating income of $34 million (compared with $57 million in Q1 2021 (-40%) and $80 million in Q2 2020 (-58%))
    • OIBD of $98 million (compared with $122 million in Q1 2021 (-20%) and $143 million in Q2 2020 (-31%))
    • Net earnings per share of $0.07 (compared with $0.29 in Q1 2021 and $0.61 in Q2 2020)
  • Following the July 2021 announcement by the Corporation regarding the monetization of its 57.6% controlling equity interest in Reno de Medici S.p.A. (RDM) for €1.45 per share, expected to result in total net proceeds of $461 million, financial information for the Boxboard Europe segment is now presented as discontinued operations. The transaction is expected to close in the third quarter of 20212.
  • Quarterly dividend increased to $0.12 per share from $0.08 per share previously, effective for the second quarter payment, resulting in an annual dividend of $0.48 per share, from $0.32 per share previously, and a return of approximately 3%.
  • Net debt1 of $1,707 million as at June 30, 2021 (compared with $1,654 million as at March 31, 2021). Net debt to adjusted OIBD ratio1, 3 of 2.9x up from 2.5x as at March 31, 2021. Net debt amount does not reflect the RDM transaction.
  • Total capital expenditures, net of disposals, of $65 million in Q2 2021, compared to $71 million in Q1 20212, and to $36 million in Q2 20202; Forecasted 2021 capital expenditures of between $400 million and $425 million, encompassing $250 million for the Bear Island containerboard conversion project in Virginia, USA.
  • S&P Global rating agency revised its outlook on the Corporation to positive from stable.

1

 Please refer to the "Supplemental Information on Non-IFRS Measures" section for a complete reconciliation.

2

 2021 and 2020 consolidated results have been adjusted to reflect retrospective adjustments of discontinued operations.

3

 Not adjusted for discontinued operations.


cascades 5aug21Mario PlourdeMario Plourde
, President and CEO, commented: "Our second quarter results were below expectations, with the sequential shortfall driven by our tissue segment. This reflected several factors, the most prominent being $12 million due to higher raw material costs and $9 million related to the net impact of sales prices and mix variance in the current period. We continued to see lower demand levels in tissue in the quarter, notably in US consumer retail product categories, as customers worked through inventories built up throughout 2020 in response to COVID-19 demand volatility. Operationally, we made the decision to temporarily curtail some tissue converting production in June to manage inventories. Notwithstanding the tissue results this quarter, we see current demand contraction as being an interim response to COVID-19 volatility given the essential nature of these products. Looking ahead, the modernization completed across our tissue platform has equipped this segment to generate important benefits when demand levels begin to normalize. On the packaging side, the Containerboard and Specialty products businesses delivered good results. Higher selling prices in Containerboard that reflect only two of the three announced price increases, coupled with good volume, were however not sufficient to fully cover raw material and production cost inflation in the second quarter, while benefits from volume growth in Specialty products more than offset the impact of higher raw material costs. A less favourable foreign exchange rate impacted the performance of all our businesses in the second quarter.

We completed an important step in our strategic plan this quarter with the announced monetization of our 57.6% equity position in Reno de Medici. This move underscores our commitment to creating long term value for the Corporation and our shareholders, and is aligned with our objective of focusing on our core North American packaging and tissue businesses. The expected net proceeds of $461 million from the transaction will improve financial flexibility and support our initiatives aimed at improving the financial performance and competitive positioning of our North American businesses. We remain dedicated to prudently and strategically deploying capital to enhance our operational platforms, while also optimizing our capital structure and evaluating opportunities to increase shareholder return including aligning our dividend return with industry averages. To this end, we are pleased to announce that we are increasing our quarterly dividend by 50% to $0.12 per share as of the second quarter of 2021, reflecting our confidence in our long-term free cash flow generation and operational performance. On an annual basis, this translates into a dividend of $0.48 per share, and increases our yield to approximately 3%."

Discussing near-term outlook, Mr. Plourde commented, "We are expecting improved results in the upcoming third quarter, supported by the roll-out of announced price increases in our Containerboard and Specialty Products segments, and a gradual normalization of demand in tissue. Notwithstanding our positive sequential outlook, the COVID-19 pandemic continues to bring with it the potential for volatility in operational and financial performance. As our second quarter results highlight, continued fluctuations in demand as well as pricing of raw materials and other input costs remain difficult to accurately predict, as does the timing and scope of economic reopening across North America. We are focused on effectively managing these uncertainties, taking decisive and necessary steps to meet the sometimes changing needs of our customers while also ensuring the safety of our employees. We are pleased with the flexibility our operations have demonstrated throughout what has been a challenging 18 months, and are very proud of the commitment and hard work of our employees."

Read more...

Source: Cascades

 

Legal Notice: Paper Advance is not responsible for the accuracy or availability of content on external websites.